Unit of Bone Tumors, Department of Orthopaedic Surgery, Arrixaca University Hospital, Murcia, Spain.
Department of Traumatology and Orthopaedia, Miguel Hernandez University, Alicante, Spain.
Knee Surg Sports Traumatol Arthrosc. 2019 Jul;27(7):2218-2225. doi: 10.1007/s00167-018-5110-4. Epub 2018 Aug 21.
To compare the outcomes of allograft-prosthesis composite for reconstruction after malignant tumors at the distal femur and proximal tibia.
Case-control study of 24 patients with distal femur tumor and 21 with proximal tibia tumor. Union of the allograft-host interface was assessed by the International Society of Limb Salvage criteria, and complications according Henderson. Functional outcome was evaluated by the Musculoskeletal Tumor Society (MSTS) score, Western Ontario and McMaster Universities (WOMAC) score, and pain by a visual analog scale.
The median follow-up in the femoral group was 11.4 (range 2.3-25.0) years, and 10.1 (range 2.2-25.0) in tibial group. Incorporation of the allograft was successful in more than 90% in both groups. Tumor location was not significant predictor for allograft failure in multivariate analysis. Aseptic prosthesis loosening occurred in two patients in either group, and another patient in the tibial group had a breakage of the tibial insert. Excluding local recurrences and amputations, the prosthesis survival at 10 years was 94.1% in the femoral group, and 83.3% in the tibial group (n.s.). For the patients with preserved limb, the median MSTS score was 23.6 in the femoral group and 22.8 in tibial group (n.s.). Likewise, there were no significant differences in median WOMAC score (n.s.) or VAS pain (n.s.).
Allograft-prosthesis composite is an effective procedure for distal femur tumors related to the graft, prosthesis survival, and functional outcomes. The results are comparable to those for proximal tibial tumors.
Therapeutic study, Level III.
比较异体-假体复合重建股骨远端和胫骨近端恶性肿瘤的结果。
对 24 例股骨肿瘤患者和 21 例胫骨肿瘤患者进行病例对照研究。根据国际保肢协会标准评估移植物-宿主界面的融合,根据 Henderson 标准评估并发症。采用肌肉骨骼肿瘤协会(MSTS)评分、安大略西部和麦克马斯特大学(WOMAC)评分评估功能结局,采用视觉模拟评分评估疼痛。
股骨组的中位随访时间为 11.4 年(范围 2.3-25.0),胫骨组为 10.1 年(范围 2.2-25.0)。两组中超过 90%的移植物均成功融合。多因素分析显示,肿瘤位置不是异体移植物失败的显著预测因素。两组各有 2 例患者发生无菌性假体松动,胫骨组另有 1 例患者胫骨插入物断裂。排除局部复发和截肢后,股骨组 10 年时假体存活率为 94.1%,胫骨组为 83.3%(无统计学意义)。对于保留肢体的患者,股骨组的 MSTS 评分中位数为 23.6,胫骨组为 22.8(无统计学意义)。同样,WOMAC 评分中位数(无统计学意义)或 VAS 疼痛(无统计学意义)也无显著差异。
异体-假体复合重建是一种有效的股骨远端肿瘤相关手术,可获得良好的移植物存活率和功能结局,结果与胫骨近端肿瘤相当。
治疗性研究,III 级。